Mumbai: Zydus Lifesciences has announced to launch artificial intelligence (AI) enabled next-generation Continuous Glucose Monitoring (CGM) devices: Diasensand GlucoLive in India.
The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem by connecting patients, caregivers, and clinicians in real time.
The devices will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes, ensuring uninterrupted capture, including overnight reading and in emergencies.
Through TatvaCareGoodFlipapp, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights.
“The launch of Diasens and GlucoLivestrengthen our companion diagnostics portfolio for chronic disease management, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control,” said Dr. Sharvil Patel, MD, Zydus Lifesciences.
